Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
C 0.88 -3.30% -0.03
VTVT closed down 8.08 percent on Monday, January 30, 2023, on 1.25 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion -3.30%
Gapped Down Weakness -3.30%
Wide Bands Range Expansion -11.11%
Overbought Stochastic Strength -11.11%
Gapped Down Weakness -11.11%
Hammer Candlestick Bullish -9.85%
Outside Day Range Expansion -9.85%
Wide Bands Range Expansion -9.85%
Overbought Stochastic Strength -9.85%
NR7 Range Contraction -10.84%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support 7 minutes ago
Down 3% 7 minutes ago
Fell Below Previous Day's Low 7 minutes ago
Down 2 % 7 minutes ago
Down 1% 7 minutes ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


vTv Therapeutics Inc. Description

vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Diabetes Autoimmune Disease Inflammation Alzheimer's Disease Parkinson's Disease Inflammatory Diseases Weakness Psoriasis Pulmonary Disease Chronic Obstructive Pulmonary Disease Organic Chemistry Pyridines Mechanical Ventilation Oxidative Stress Treatment Of Alzheimer's Disease Treatment Of Chronic Obstructive Pulmonary Disease Tyrosine Kinase Inhibitors Biotie Therapies Phosphodiesterase Buparlisib Treatment Of Inflammation

Is VTVT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.4
52 Week Low 0.382
Average Volume 71,167
200-Day Moving Average 0.83
50-Day Moving Average 0.81
20-Day Moving Average 0.87
10-Day Moving Average 0.97
Average True Range 0.06
RSI 56.14
ADX 41.78
+DI 24.43
-DI 17.74
Chandelier Exit (Long, 3 ATRs) 0.86
Chandelier Exit (Short, 3 ATRs) 0.84
Upper Bollinger Bands 1.08
Lower Bollinger Band 0.66
Percent B (%b) 0.6
BandWidth 48.95
MACD Line 0.06
MACD Signal Line 0.05
MACD Histogram 0.008
Fundamentals Value
Market Cap 47.17 Million
Num Shares 51.8 Million
EPS -0.56
Price-to-Earnings (P/E) Ratio -1.62
Price-to-Sales 4106.62
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.08
Resistance 3 (R3) 1.09 1.05 1.05
Resistance 2 (R2) 1.05 1.00 1.04 1.04
Resistance 1 (R1) 0.98 0.98 0.96 0.97 1.03
Pivot Point 0.93 0.93 0.92 0.93 0.93
Support 1 (S1) 0.86 0.89 0.84 0.85 0.79
Support 2 (S2) 0.82 0.86 0.81 0.78
Support 3 (S3) 0.75 0.82 0.77
Support 4 (S4) 0.74